Honolulu, HINCT04965454Now EnrollingIRB Ready

Hepatocellular Carcinoma Non-resectable Clinical Trial in Honolulu, HI

Access cutting-edge hepatocellular carcinoma non-resectable treatment through this clinical trial at a research site in Honolulu. Study-provided care at no cost to qualified participants.

Sponsored by Queen's Medical Center

Quick Self-Assessment

See if you qualify for this Honolulu location

Preparing your pre-screening questions…

Expert Care in Honolulu

Access hepatocellular carcinoma non-resectable specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hepatocellular carcinoma non-resectable treatment provided free

Apply for This Honolulu Location

Check if you qualify for this hepatocellular carcinoma non-resectable clinical trial in Honolulu, HI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Honolulu

    Convenient for HI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Honolulu site if eligible
  4. 4Begin participation

About This Hepatocellular Carcinoma Non-resectable Study in Honolulu

This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this diagnostic trial is to assess the accuracy of pre-treatment fluorine-18 (18F-) fluorocholine (FCH) PET/CT for predicting a lack of objective response (LOR) after 16 weeks of ICI therapy.

Sponsor: Queen's Medical Center

Who Can Participate

Inclusion Criteria

Age 18 years or older (no upper limit of age)
Hepatocellular carcinoma diagnosis made histologically or radiographically in accordance to National Comprehensive Cancer Network guidelines (3.2019 version or higher)
Does not qualify for surgical resection or locoregional therapy alone or has disease that has progressed after surgical resection and/or locoregional therapy
Has measurable disease defined as at least one tumor lesion that can be accurately measured according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 on CT/MRI completed within past 6 weeks of eligibility screening
Under the care of a licensed medical oncologist
Life expectancy \> 6 months
Deemed eligible for treatment with an immune checkpoint inhibitor agent based on the treating medical oncologist's assessment of previous treatment failure, clinical/performance/virology status, and liver/renal/hematologic function.
Child-Pugh score of 9 or less
Creatinine clearance ≥ 40 mL/min, measured or calculated using the Cockcroft-Gault formula
ALT and AST ≤7x upper limit of normal
Total bilirubin ≤4 mg/dL
Albumin ≥2.8 g/dL

Exclusion Criteria

Weight \> 500 lbs (PET/CT limit)
Pregnant or lactating female (those of child-bearing potential must be re-screened within 7 days prior to PET/CT imaging)
Serious underlying medical condition that would impair patient's ability to tolerate the imaging procedure
Concurrent treatment with a non-targeted therapeutic agent. Concurrent enrollment in an ICI-treatment trial and combination ICI treatment are allowed.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Honolulu?

Yes, this clinical trial (NCT04965454) has an active research site in Honolulu, HI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hepatocellular Carcinoma Non-resectable Treatment Options in Honolulu, HI

If you're searching for hepatocellular carcinoma non-resectable treatment options in Honolulu, HI, this clinical trial (NCT04965454) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Honolulu research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hepatocellular carcinoma non-resectable specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hepatocellular carcinoma non-resectable clinical trials near you to find additional studies recruiting in your area.

More Liver Cancer Trials in Honolulu, HI

See all liver cancer clinical trials recruiting in Honolulu — not just this study.

Browse Liver Cancer Trials in Honolulu →

Browse More Trials by Condition

Liver Cancer TrialsAll Conditions →

Ready to Join in Honolulu?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Honolulu, HI